摘要
近年来,肺癌的治疗发生了翻天覆地的变化,针对免疫检查点的免疫治疗显著改善了晚期肺癌患者的生存。多项随机对照研究证实,在二线治疗中,与标准化疗相比免疫治疗可显著延长患者的总生存期,因此免疫治疗目前已成为晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的标准二线治疗。近期一些研究还奠定了免疫治疗联合化疗在一线治疗中的地位。然而,免疫治疗总有效率方法不高,目前尚缺乏精准的疗效预测分子标志物,本文对目前肺癌免疫治疗的进展以及未来的发展方向进行了综述。
In recent years, the treatment of lung cancer has undergone earth-shaking changes. The application for immunotherapy targeting immune checkpoint has significantly improved the survival outcomes of advanced lung cancer patients. Several randomized-controlled trials have shown that immunotherapy significantly improves the overall survival of advanced non-small cell lung cancer(NSCLC) patients when compared with standard chemotherapy in second-line setting. Therefore, immunotherapy is the standard second-line therapy currently. Several clinical trials have also demonstrated the role of immunotherapy in combination with chemotherapy in first-line setting. However, it should be noted that the overall response rate of immunotherapy is not high enough, and it currently lacks of accurately predictive biomarkers for immunotherapy. This article summarizes the current progress of immunotherapy for lung cancer and also provides insights into future directions.
作者
潘莹莹
周斐
周彩存
PAN Yingying;ZHOU Fei;ZHOU Caicun(Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200433, China)
出处
《中国癌症杂志》
CAS
CSCD
北大核心
2019年第4期241-249,共9页
China Oncology
关键词
肺癌
免疫治疗
进展与挑战
Lung cancer
Immunotherapy
Progress and challenge
